WO2005075425A3 - Substituted bisarylurea derivatives as kinase inhibitors - Google Patents
Substituted bisarylurea derivatives as kinase inhibitors Download PDFInfo
- Publication number
- WO2005075425A3 WO2005075425A3 PCT/EP2005/000387 EP2005000387W WO2005075425A3 WO 2005075425 A3 WO2005075425 A3 WO 2005075425A3 EP 2005000387 W EP2005000387 W EP 2005000387W WO 2005075425 A3 WO2005075425 A3 WO 2005075425A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kinase inhibitors
- bisarylurea derivatives
- substituted bisarylurea
- formula
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0507198-4A BRPI0507198A (en) | 2004-01-30 | 2005-01-17 | bisarylurea derivatives |
JP2006549997A JP2007519653A (en) | 2004-01-30 | 2005-01-17 | Bisaryl urea derivatives |
AU2005211448A AU2005211448A1 (en) | 2004-01-30 | 2005-01-17 | Bisarylurea derivatives |
EP05700967A EP1730111A2 (en) | 2004-01-30 | 2005-01-17 | Substituted bisarylurea derivatives as kinase inhibitors |
CA002554878A CA2554878A1 (en) | 2004-01-30 | 2005-01-17 | Bisarylurea derivatives |
US10/587,292 US20070161677A1 (en) | 2004-01-30 | 2005-01-17 | Bisarylurea derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04002092.7 | 2004-01-30 | ||
EP04002092 | 2004-01-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005075425A2 WO2005075425A2 (en) | 2005-08-18 |
WO2005075425A3 true WO2005075425A3 (en) | 2006-12-14 |
Family
ID=34833556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/000387 WO2005075425A2 (en) | 2004-01-30 | 2005-01-17 | Substituted bisarylurea derivatives as kinase inhibitors |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070161677A1 (en) |
EP (1) | EP1730111A2 (en) |
JP (1) | JP2007519653A (en) |
KR (1) | KR20060132882A (en) |
CN (1) | CN1972925A (en) |
AR (1) | AR047585A1 (en) |
AU (1) | AU2005211448A1 (en) |
BR (1) | BRPI0507198A (en) |
CA (1) | CA2554878A1 (en) |
RU (1) | RU2006131045A (en) |
WO (1) | WO2005075425A2 (en) |
ZA (1) | ZA200607220B (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
MXPA04007832A (en) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aryl ureas with angiogenesis inhibiting activity. |
CA2526617C (en) | 2003-05-20 | 2015-04-28 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
UA84156C2 (en) | 2003-07-23 | 2008-09-25 | Байер Фармасьютикалс Корпорейшн | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
EP1751139B1 (en) | 2004-04-30 | 2011-07-27 | Bayer HealthCare LLC | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
BRPI0515991A (en) | 2004-10-13 | 2008-08-19 | Merck Patent Gmbh | heterocyclically substituted bisarylurea derivatives as kinase inhibitors |
JP2009518298A (en) * | 2005-12-01 | 2009-05-07 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | Urea compounds useful for cancer treatment |
CA2634084C (en) * | 2005-12-21 | 2015-04-07 | Roger Smith | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders |
TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
WO2007107352A1 (en) * | 2006-03-21 | 2007-09-27 | The European Molecular Biology Laboratory | Agents that disrupt cellular replication and their use in inhibiting pathological conditions |
CA2649000A1 (en) * | 2006-04-12 | 2007-10-18 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
RU2012114902A (en) | 2009-09-16 | 2013-10-27 | Авила Терапьютикс, Инк. | CONJUGATES AND PROTEINKINASE INHIBITORS |
CN101717373B (en) * | 2009-11-09 | 2012-06-20 | 东南大学 | Diaryl urea derivative and application thereof |
WO2011068187A1 (en) * | 2009-12-04 | 2011-06-09 | 第一三共株式会社 | Quinazoline derivatives |
CA2785738A1 (en) | 2009-12-30 | 2011-07-07 | Avila Therapeutics, Inc. | Ligand-directed covalent modification of protein |
KR20130044382A (en) * | 2010-03-01 | 2013-05-02 | 마이렉시스 인코포레이티드 | Compounds and therapeutic uses thereof |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
CN102617458A (en) * | 2010-05-18 | 2012-08-01 | 张南 | Preparation method for anticancer compound |
CN101830847B (en) * | 2010-05-18 | 2012-10-10 | 张南 | Anticancer compound and preparation method thereof |
CN102408426B (en) * | 2011-09-14 | 2013-07-10 | 湖南有色凯铂生物药业有限公司 | Substituted aromatic urea compound and application as anticancer medicament thereof |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
CN103319402B (en) * | 2012-03-22 | 2015-01-14 | 齐鲁制药有限公司 | Diphenyl thiourea derivatives, preparation method and applications thereof |
CN103788065A (en) * | 2012-10-31 | 2014-05-14 | 韩冰 | Compound for protecting transplanted organs and application thereof |
US10196378B2 (en) | 2016-08-25 | 2019-02-05 | The Regents Of The University Of Michigan | Inhibitors of BCR-ABL mutants and use thereof |
CN106748991B (en) * | 2016-11-14 | 2020-03-17 | 西安交通大学 | Diaryl urea compound with anti-tumor activity and preparation method and application thereof |
CN106748990A (en) * | 2016-11-14 | 2017-05-31 | 西安交通大学 | A kind of substituted bisarylurea compound with antitumor activity and its preparation method and application |
CN106748989B (en) * | 2016-11-14 | 2020-03-17 | 西安交通大学 | Diaryl urea compound with anti-tumor activity and preparation method and application thereof |
WO2018141642A1 (en) * | 2017-02-06 | 2018-08-09 | BASF Agro B.V. | Process for the preparation of 2-chloro-4-fluoro-5-nitrobenzotrichloride |
US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
LT3691620T (en) | 2017-10-05 | 2022-09-26 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
CN113264874A (en) * | 2021-05-21 | 2021-08-17 | 华东理工大学 | Substituted diaryl urea derivative and preparation method and application thereof |
CN113603616B (en) * | 2021-07-05 | 2023-03-07 | 安徽医科大学 | Paeonol derivative, and preparation method, preparation and application thereof |
WO2023222332A1 (en) * | 2022-05-16 | 2023-11-23 | Merck Patent Gmbh | Diphenyl ureas for the treatment of viral infections |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4191767A (en) * | 1977-01-07 | 1980-03-04 | Westwood Pharmaceuticals, Inc. | Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines |
WO1999032436A1 (en) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
US20030144278A1 (en) * | 2001-01-12 | 2003-07-31 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2003099771A2 (en) * | 2002-05-29 | 2003-12-04 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE297383T1 (en) * | 1997-12-22 | 2005-06-15 | Bayer Pharmaceuticals Corp | INHIBITION OF P38 KINASE USING SYMMETRIC AND ASYMMETRIC DIPHENYL UREASES |
MXPA00006233A (en) * | 1997-12-22 | 2002-09-18 | Bayer Ag | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS. |
EP2298311B1 (en) * | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
DE60026822T2 (en) * | 1999-01-13 | 2006-08-24 | Bayer Pharmaceuticals Corp., West Haven | -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREAIDS AS RAF KINASE INHIBITORS |
MXPA02004879A (en) * | 1999-11-16 | 2002-08-30 | Boehringer Ingelheim Pharma | Urea derivatives as anti inflammatory agents. |
MXPA04007832A (en) * | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aryl ureas with angiogenesis inhibiting activity. |
WO2003068746A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
-
2005
- 2005-01-17 WO PCT/EP2005/000387 patent/WO2005075425A2/en active Application Filing
- 2005-01-17 AU AU2005211448A patent/AU2005211448A1/en not_active Abandoned
- 2005-01-17 RU RU2006131045/04A patent/RU2006131045A/en unknown
- 2005-01-17 CN CNA2005800029013A patent/CN1972925A/en active Pending
- 2005-01-17 US US10/587,292 patent/US20070161677A1/en not_active Abandoned
- 2005-01-17 JP JP2006549997A patent/JP2007519653A/en active Pending
- 2005-01-17 CA CA002554878A patent/CA2554878A1/en not_active Abandoned
- 2005-01-17 EP EP05700967A patent/EP1730111A2/en not_active Withdrawn
- 2005-01-17 KR KR1020067015303A patent/KR20060132882A/en not_active Application Discontinuation
- 2005-01-17 BR BRPI0507198-4A patent/BRPI0507198A/en not_active Application Discontinuation
- 2005-01-28 AR ARP050100299A patent/AR047585A1/en unknown
-
2006
- 2006-08-29 ZA ZA200607220A patent/ZA200607220B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4191767A (en) * | 1977-01-07 | 1980-03-04 | Westwood Pharmaceuticals, Inc. | Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines |
WO1999032436A1 (en) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
US20030144278A1 (en) * | 2001-01-12 | 2003-07-31 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2003099771A2 (en) * | 2002-05-29 | 2003-12-04 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
Non-Patent Citations (5)
Title |
---|
DATABASE BEILSTEIN [online] XP002387488, Database accession no. 163948 * |
DYCK B ET AL: "Aryl piperazine melanocortin MC4 receptor agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 13, no. 21, 3 November 2003 (2003-11-03), pages 3793 - 3796, XP002279632, ISSN: 0960-894X * |
KRBECHEK, L. ET AL.: "The thermal decomposition of benzylidene-2-azidoanilines", J. ORG. CHEM., vol. 29, 1964, pages 3630 - 3632, XP002387486 * |
KREMER, C.B. ET AL.: "Morpholine condensations", J. AM. CHEM. SOC., vol. 61, 1939, pages 2552 - 2552, XP002387485 * |
PRELOG & BLAZEK, COLLECT. CZECH. CHEM. COMMUN., vol. 6, 1934, pages 211 - 218 * |
Also Published As
Publication number | Publication date |
---|---|
CN1972925A (en) | 2007-05-30 |
EP1730111A2 (en) | 2006-12-13 |
BRPI0507198A (en) | 2007-06-26 |
US20070161677A1 (en) | 2007-07-12 |
AR047585A1 (en) | 2006-01-25 |
CA2554878A1 (en) | 2005-08-18 |
AU2005211448A1 (en) | 2005-08-18 |
WO2005075425A2 (en) | 2005-08-18 |
ZA200607220B (en) | 2008-05-28 |
RU2006131045A (en) | 2008-03-10 |
JP2007519653A (en) | 2007-07-19 |
KR20060132882A (en) | 2006-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
MX2007004248A (en) | Heterocyclic substituted bisarylurea derivatives as kinase inhibitors. | |
WO2004037789A8 (en) | Methylene urea derivatives as raf-kinase inhibitors | |
WO2006011050A3 (en) | Pyridine derivatives | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
WO2006099943A8 (en) | Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments | |
WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
WO2007082808A3 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
WO2005086656A3 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
WO2005080352A3 (en) | Quinazoline derivatives and therapeutic use thereof | |
TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
WO2008013838A3 (en) | Pyridizinone derivatives | |
WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
WO2008067119A3 (en) | Novel compounds | |
WO2007135527A3 (en) | Benzimidazolyl compounds | |
TW200833663A (en) | Therapeutic agents | |
WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
WO2008002244A8 (en) | Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3) | |
GB0112348D0 (en) | Compounds | |
WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
WO2007009721A3 (en) | Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
WO2005005389A3 (en) | Malonamide derivatives | |
WO2008131946A3 (en) | Substituted amide derivatives | |
WO2007130821A3 (en) | Mglur5 modulators ii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005700967 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006501184 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580002901.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007161677 Country of ref document: US Ref document number: 10587292 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/008449 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2554878 Country of ref document: CA Ref document number: 2006549997 Country of ref document: JP Ref document number: 1020067015303 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2441/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/07220 Country of ref document: ZA Ref document number: 200607220 Country of ref document: ZA Ref document number: 2005211448 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006131045 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2005211448 Country of ref document: AU Date of ref document: 20050117 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005211448 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005700967 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067015303 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0507198 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10587292 Country of ref document: US |